939986-79-5

Basic information

• Product Name: 4-[(6-Chloro-pyriMidin-4-ylaMino)-Methyl]-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H23ClN4O2, MW: 326.82
• Synonyms: 4-[(6-Chloro-pyriMidin-4-ylaMino)-Methyl]-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H23ClN4O2, MW: 326.82;4-[[(6-Chloro-4-pyrimidinyl)amino]methyl]-1-piperidinecarboxylic acid tert-butyl ester;tert-Butyl 4-[[(6-chloropyrimidin-4-yl)amino]methyl]piperidine-1-carboxylate;4-[(6-Chloro-pyrimidin-4-ylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl est
• CAS NO: 939986-79-5
• Molecular Formula: C15H23ClN4O2
• Molecular Weight: 326.82172
• Mol File: 939986-79-5.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.219
• CAS DataBase Reference: 4-[(6-Chloro-pyriMidin-4-ylaMino)-Methyl]-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H23ClN4O2, MW: 326.82(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(6-Chloro-pyriMidin-4-ylaMino)-Methyl]-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H23ClN4O2, MW: 326.82(939986-79-5)
• EPA Substance Registry System: 4-[(6-Chloro-pyriMidin-4-ylaMino)-Methyl]-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H23ClN4O2, MW: 326.82(939986-79-5)

Safety Data

• Hazardous Substances Data: 939986-79-5(Hazardous Substances Data)

Upstream product

• 1193-21-1 4,6-dichloropyrimidine 
• 144222-22-0 tert-butyl 4-(aminomethyl)piperidine-1-carboxylate 

Relevant articles and documents

PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin- 2 - yl -pyridin- 2 -yl -amine and pyrazine - 2 - yl -pyrimidin- 4 - yl -amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1 ) kinase function The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1. that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or Il inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisiπq radiation. wherein: -X= is independently -CRA5= or -N=; and the rest of the substituents are as specified in the claims.